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Combining functional scales and cognitive tests 
in screening for mild cognitive impairment at a 
university-based memory clinic in Brazil
Combinação de escalas funcionais e testes cognitivos 
para rastreio de comprometimento cognitivo leve em 
ambulatório universitário de memória no Brasil
Abstract
Objective: To determine the diagnostic accuracy of the Mini-Mental State Examination combined to the Informant Questionnaire on 
Cognitive Decline in the Elderly for the identification of mild cognitive impairment. Method: 191 elderly subjects were assessed with the 
Mini-Mental State Examination, and their informants were assessed with the Informant Questionnaire on Cognitive Decline in the Elderly. 
Subjects were divided into three groups according to their cognitive state (controls: n = 67, mild cognitive impairment: n = 65 and 
dementia: n = 59), which was ascertained by clinical and neuropsychological evaluation. The diagnostic accuracy of each test in the 
discrimination of diagnostic groups (mild cognitive impairment vs. controls, mild cognitive impairment vs. dementia and dementia vs. 
controls) was examined with the aid of ROC curves. We additionally verified if the combination of both tests would increase diagnostic 
accuracy for mild cognitive impairment and control identification. Results: The combination of the Mini-Mental State Examination and 
the Informant Questionnaire on Cognitive Decline in the Elderly scores did not increase the Mini-Mental State Examination diagnostic 
accuracy in the identification of patients with mild cognitive impairment. Conclusions: The present data do not warrant the combination 
of the Mini-Mental State Examination and the Informant Questionnaire on Cognitive Decline in the Elderly as a sufficient diagnostic tool 
in the diagnostic screening for mild cognitive impairment. 
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Resumo
Objetivo: Avaliar a acurácia diagnóstica do Mini-Exame do Estado Mental combinado ao Questionário do Informante sobre Declínio 
Cognitivo na identificação de casos de comprometimento cognitivo leve. Método: 191 indivíduos idosos foram avaliados com o 
Mini-Exame do Estado Mental e seus informantes com o Questionário do Informante sobre Declínio Cognitivo. Os indivíduos foram 
divididos em três grupos de acordo com o estado cognitivo (controles: n = 67; comprometimento cognitivo leve: n = 65; demência: 
n = 59), segundo avaliação clínica e neuropsicológica. Pela análise de curvas ROC, avaliamos a acurácia diagnóstica de cada teste para 
diferenciar os grupos diagnósticos (comprometimento cognitivo leve vs. controles; comprometimento cognitivo leve vs. demência; 
demência vs. controles). Adicionalmente, verificamos se a combinação dos dois testes fortalece a acurácia diagnóstica para a separação 
dos casos de comprometimento cognitivo leve dos controles normais. Resultados: A análise combinada do Questionário do Informante 
sobre Declínio Cognitivo e Mini-Exame do Estado Mental não aumentou a acurácia diagnóstica do Mini-Exame do Estado Mental 
em predizer a ocorrência de comprometimento cognitivo leve. Conclusões: Os dados deste estudo não sustentam a utilidade clínica 
da combinação dos escores do Mini-Exame do Estado Mental e do Questionário do Informante sobre Declínio Cognitivo no rastreio 
diagnóstico do comprometimento cognitivo leve.
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Introduction
The recognition of symptoms indicative of the risk of dementia 
in older adults is important, given the prospect of the development 
of drugs with disease-modifying properties, which would be more 
efficacious if started in the early stages of the disease.1 At present, 
the best attempt to characterize such individuals is the definition 
of mild cognitive impairment (MCI), which refers to subjects with 
or without subjective cognitive complaints, objective impairment in 
cognitive assessment (provided scores are corrected for relation to 
age and educational level), minimal or no evidence of impairment 
in the performance of daily activities, and not demented.2 In most 
studies, the neuropsychological evaluation remains as the gold 
standard for diagnosis of MCI. Nonetheless, a comprehensive 
neuropsychological evaluation is costly, time-consuming, and 
demands well-trained professionals, thus hindering its widespread 
use in primary care. Therefore, MCI patients may not be easily 
recognized in primary clinical settings, delaying the proper 
identification of subjects with an increased risk of dementia.
Cognitive screening tests can be divided into two broad categories: 
tests that objectively assess the cognitive performance (e.g. the Mini-
Mental State Examination - MMSE, the Clock Drawing Test), and 
informant-based questionnaires (e.g. the Informant Questionnaire of 
Cognitive Decline in the Elderly - IQCODE). The MMSE is the most 
widely used cognitive screening test and has been validated in several 
languages and cultures for the diagnostic screening of dementia. The 
IQCODE is an informant-based questionnaire that compares the patient’s 
present ability to perform several activities of the daily living, and tasks 
that demand intact recent episodic memory and intellectual abilities over 
a continuum of 10 years. It is composed of 26 items individually scored 
from 1-“much better” to 5 -“much worse”. Intermediate scores of 2 and 
4 indicate slightly better or worse, respectively; score of 3 indicates no 
significant changes in comparison to 10 years ago. The final score is 
given by the sum of the 26-item scores divided by 26, and it ranges 
from 1 to 5, with higher scores indicating worse functional status.3
The IQCODE is supposedly not unaffected by education, premorbid 
intellectual ability, or by proficiency in the culture’s dominant language.4
On the other hand, because the IQCODE relies on the information 
provided by a caregiver or a close relative of the patient, scores may 
be biased by the informant’s cognitive and emotional state (such as 
depression and anxiety) or personality traits, and by the other factors 
affecting the relationship between the informant and the patient. These 
factors can both minimize or maximize the actual deficits. The IQCODE 
has been shown to have a good sensitivity and specificity to identify cases 
of dementia,5 but very few studies have so far addressed the diagnostic 
properties of the IQCODE in the diagnostic screening of MCI.
Previous reports showed that the association of cognitive 
screening tests improves the potential of a single test to differentiate 
individuals with Alzheimer’s disease (AD) from unimpaired elderly 
patients.6 Therefore, the aim of this work is to ascertain whether 
the association of two widely used cognitive screening tests, i.e. the 
MMSE and the IQCODE, is more accurate than each test alone to 
discriminate cognitively unimpaired elderly subjects from patients 
with MCI and AD. We hypothesize that the association of these two 
screening instruments have a higher accuracy in the identification 
of cognitive impairment than either test alone.
Method
1. Patients 
One hundred and ninety-one elderly patients (67 controls, 65 
MCI, and 59 AD) were assessed at a university-based memory clinic 
from December 2001 to May 2006. Age and educational level 
for patients and controls are presented in Table 1. Patients were 
recruited from community sources for the assessment of suspected 
cognitive decline in São Paulo, Brazil. This study was approved 
by the Ethical Committee of Hospital das Clínicas University of 
São Paulo (protocol number: 1032/07), and was performed in 
accordance with the Helsinki Declaration. 
2. Clinical assessment 
The cognitive assessment and the diagnostic procedures in this 
cohort are described in details in previously published studies.7
In brief, patients were examined by clinicians specialized in the 
evaluation of cognitive disorders. The clinical assessment included 
the Cambridge Mental Disorders of the Elderly Examination 
(CAMDEX) interview, which yields the Cambridge Cognitive 
Examination (CAMCOG) and the MMSE scores. The IQCODE was 
further administered to a close relative or caregiver of each subject. 
The 21-item Hamilton Depression Scale8 was administered to 
rule out depressive symptoms. Evidence of functional decline was 
suggested by the informant’s or the patient’s report of difficulties 
performing activities of daily living. The neuropsychological 
evaluation was carried out as the gold standard for the diagnosis 
of MCI and AD as described in previous studies.9 It included the 
Rivermead Behavioral Memory Test (RBMT), the Fuld Object-
Memory Evaluation (FOME), the Trail Making Test (TMT) A and B, 
the Short Cognitive Test (SKT) and the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R) Vocabulary and Block Design tests. The 
neuropsychologists responsible for the assessments were blinded to 
the MMSE and IQCODE scores when the tests were administered. 
For the sake of conciseness, only the scores for the IQCODE and 
the MMSE will be reported in this paper (Table 1).
3. Diagnosis 
Clinical diagnoses were reached by consensus at expert 
multi-disciplinary meetings, taking into account clinical, 
neuropsychological, laboratorial, and neuroimaging data. The 
MMSE and IQCODE scores per se were not taken into account 
for establishing the clinical diagnosis. Dementia was diagnosed 
according to the DSM-IV criteria.10 In this study, we included patients 
that fulfilled the diagnostic criteria for AD according to the NINCDS-
ADRDA11 or for MCI according to Petersen et al.,12 in addition 
to cognitively unimpaired age-matched controls. Patients with 
evidence of depressive or anxiety disorders were excluded from the 
study, as well as patients with other dementia syndromes, such as 
vascular dementia and other neurodegenerative diseases, diagnosed 
according to the currently accepted diagnostic criteria.13-15
4. Statistical analysis 
Non-parametric statistics were performed to assess median 
differences between the diagnostic groups (Kruskall Wallis test), 
while analysis of variance (ANOVA) was performed to control for 
the variable age. Backward stepwise logistic regression analysis was 
performed to assess whether the two tests used together provided 
any additional information for predicting MCI over that given by 
either test used alone. Receiving Operating Characteristics (ROC) 
analyses were performed for each test comparing the diagnostic 
group in a two-by-two fashion. The accuracy of each test, and 
of their association, is represented by the area under the curve 
(AUC). In addition, cutoff values and the respective sensitivity and 
specificity values were drawn by ROC analyses. ROC curves were 
also constructed for the combination of the tests for MCI accuracy 
according to the Mackinnon and Mulligan’s weighted sum rule.16
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‘Logit (case)’ is the logarithm of the odds of a subject being a case 
of dementia. The IQCODE and the MMSE are the test score values, 
and the derivation of these values is influenced by the characteristics 
of the sample.
Weighted sum formula: Logit (case) = 1.4508 + 1.5819 x IQCODE-
0.3119 x MMSE.
All statistical analyses were performed using SPSS v14.0 for 
Windows (SPSS Inc., Chicago, IL) and statistic significance was 
set at A = 5%. 
Results 
ROC curve analysis performed in the subsample of patients with 
MCI and controls indicated that the cutoff scores that yielded the 
best diagnostic accuracy were 28 for the MMSE (area under the ROC 
curve) AUC: 0.70 (p < 0.001); sensitivity, SS: 73.5%; specificity, 
SP: 61.5%; positive predictive value, PPV: 49.6%; negative 
predictive value, NPV: 81.8%; 3.11 for the IQCODE, AUC: 0.62 
(p < 0.001); SS: 69.2%; SP: 49.3%; PPV: 41.3%; NPV: 75.6%. 
The weighted sum (MMSE combined with IQCODE) indicated a 
diagnostic accuracy similar to the MMSE alone, and slightly better 
than the IQCODE alone [AUC: 0.70 (p < 0.001); SS: 73.8%; SP: 
62.7%; PPV: 50.5%; NPV: 82.2%]. Additionally, the cutoff scores 
that best differentiated patients with dementia from controls in the 
current sample were 25 for the MMSE [AUC: 0.975 (p < 0.001); 
SS: 88.7%; SP: 94.8%; PPV: 93.2%; NPV: 91.4%] and 3.3 for 
the IQCODE [AUC: 0.847 (p < 0.001); SS: 83.6%; SP: 80.6%; 
PPV: 72.3%; NPV: 84.2%].
In the logistic regression analysis for the MCI and Control group, 
using the IQCODE and the MMSE co-variables together, the more 
the IQCODE scores the higher is the risk of having MCI comparing to 
lower scores (IQCODE: Odds Ratio (OR): 2.34; p: 0.192; Confidence 
Interval (CI): 0.65-8.44), but p value is not statistically significant 
and the wide CI gives less credibility to the results. Only the MMSE 
was statistically significant in this analysis showing that the lower 
the score, the higher the risk of having MCI (OR: 0.725; p: 0.001; 
CI: 0.604-0.871).
Discussion
Our results showed that although the MMSE and the IQCODE 
are adequate instruments for the diagnostic screening for dementia, 
neither test had a good diagnostic accuracy for identification of 
cases of MCI. In addition, the combined use of these tests did not 
increase the aforementioned diagnostic properties. Our results are in 
accordance with previously published studies in which these tests 
used alone or in combination in the screening for dementia,17 but are in 
disagreement with a recent publication by Isella et al.,18 who suggested 
that the IQCODE had a good discriminative power between cognitively 
unimpaired older adults and patients with MCI. In this study, with similar 
cutoff values (28 for the MMSE and 3.19 for the IQCODE), both tests had 
a similar discriminative accuracy, but higher than in the current sample 
(AUC: 0.86 and 0.84, respectively). Differences in diagnostic procedures 
and definitions of cognitive decline may account for the differences in 
the latter and the current study. In the present sample, the diagnosis of 
MCI was based on the output of a comprehensive neuropsychological 
assessment, which probably results in the inclusion of patients with 
milder degrees of cognitive impairment.
This study highlights two important aspects that may have practical 
implications for the diagnostic work-up of cognitive disorders. 
Firstly, the combination of the MMSE and the IQCODE does not 
seem sufficiently accurate for the identification of cases of MCI, 
although it is a frequent procedure in clinical practice. Secondly, 
the diagnosis of MCI still depends on the information provided by 
a comprehensive neuropsychological assessment. The complexity 
of this procedure is a limitation for the large-scale diagnosis of 
MCI, particularly in primary care settings. The diagnosis of MCI 
is undoubtedly associated with an increased risk of developing 
dementia in the long-term outcome. However, it is by no means a 
synonymous of any given neurodegenerative condition. From the 
clinician’s perspective, a careful judgment based on detailed clinical 
and neuropsychological data, in addition to reliable information 
on the patient’s functional status, preferentially corroborated by 
longitudinal reassessments, is still the best approach for the detection 
of relevant cognitive impairment, and to estimate the actual risk of 
the dementia outcome.19
Conclusion
In summary, the IQCODE, the MMSE, and their combined use 
had low sensitivity for the screening of MCI patients. Therefore, the 
development of new cognitive screening strategies are mandatory 
for the identification of such cases and further analyses, in this 
population, are underway to evaluate which of the 26 IQCODE 
questions or clusters of them better characterize the MCI patients 
and its subtypes.
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Table 1 – Demographic variables
Total score Controls (n = 67) MCI (n = 65) Dementia (n = 59) P value
Age (Mean ± StandardDeviation (SD) 67.7 ± 6.31 70.46 ± 6.43 75.56 ± 7.73 < 0.001
Educational level (years) (Mean ± SD) 14.42 ± 5.30 10.63 ± 5.15 7.58 ± 5.25 < 0.001
IQCODE (Mean ± SD) 3.19 ± 0.23 3.30 ± 0.37 3.80 ± 0.55 < 0.001
MMSE (Mean ± SD) 28.36 ± 1.69 26.69 ± 2.75 20.24 ± 4.46 < 0.001
Age: ANOVA
MMSE, IQCODE, Educational level: Kruskal Wallis 
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